Yutaka Kurebayashi
Overview
Explore the profile of Yutaka Kurebayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
816
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aoki T, Nishida N, Kurebayashi Y, Sakai K, Fujiwara N, Tsurusaki M, et al.
Clin Mol Hepatol
. 2025 Mar;
PMID: 40065709
Background/aims: Previously, we advocated the importance of classifying hepatocellular carcinoma (HCC) based on physiological functions. This study aims to classify HCC by focusing on liver-intrinsic metabolism and glycolytic pathway in...
2.
Tsuzaki J, Ueno A, Masugi Y, Tamura M, Yamazaki S, Matsuda K, et al.
Jpn J Clin Oncol
. 2025 Jan;
PMID: 39775861
Purpose: To achieve a historical perspective, the chronological changes in primary liver cancer over a 20-year period were investigated at a single institution, focusing on shifts in etiology and the...
3.
Matsuda K, Ueno A, Tsuzaki J, Kurebayashi Y, Masugi Y, Yamazaki K, et al.
Hepatol Commun
. 2024 Dec;
9(1).
PMID: 39670871
Background: Vessels encapsulating tumor clusters (VETC) pattern is tumor vasculature of HCC and is a predictor of prognosis and therapeutic efficacy. Recent radiological studies have demonstrated the predictability of VETC...
4.
Kurebayashi Y, Sugimoto K, Tsujikawa H, Matsuda K, Nomura R, Ueno A, et al.
Clin Cancer Res
. 2024 Oct;
30(24):5666-5680.
PMID: 39417698
Purpose: Immunotherapies have led to a paradigm shift in the treatment of hepatocellular carcinoma (HCC). Studies have revealed the single-cell catalogs of tumor-infiltrating immune cells and the trajectories of their...
5.
Effendi K, Rahadiani N, Stephanie M, Kurebayashi Y, Tsujikawa H, Jasirwan C, et al.
J Clin Exp Hepatol
. 2024 Jul;
14(6):101451.
PMID: 38975604
Background: Standardized pathological evaluation based on immunohistochemical (IHC) analysis could improve hepatocellular carcinoma (HCC) diagnoses worldwide. We evaluated differences in clinicopathological subgroups in HCCs from two academic institutions in Tokyo-Japan,...
6.
Aoki T, Nishida N, Kurebayashi Y, Sakai K, Morita M, Chishina H, et al.
Liver Cancer
. 2024 Jun;
13(3):285-305.
PMID: 38894812
Introduction: Immunotherapy is becoming a promising approach for unresectable-hepatocellular carcinoma (HCC); the anti-tumor response is affected by the tumor microenvironment (TME). Although Wnt/β-catenin mutations are reported to cause non-inflamed phenotype,...
7.
Fujimori S, Chu P, Teratani T, Harada Y, Suzuki T, Amiya T, et al.
JHEP Rep
. 2023 Jun;
5(7):100757.
PMID: 37305442
Background & Aims: B-cell depletion therapy with an anti-CD20 is an effective treatment strategy for patients with refractory autoimmune hepatitis (AIH). However, the mechanisms underlying B-cell action are unclear. Methods:...
8.
Kurebayashi Y, Tsujikawa H, Sugimoto K, Yunaiyama D, Araki Y, Saito K, et al.
Hepatol Res
. 2023 Jun;
53(10):1008-1020.
PMID: 37300323
Aim: The anti-programmed death-ligand 1 antibody atezolizumab and vascular endothelial growth factor-neutralizing antibody bevacizumab in combination (Atezo + Bev) have become the first-line therapy in advanced hepatocellular carcinoma (HCC). Distinct...
9.
Matsuda K, Kurebayashi Y, Masugi Y, Yamazaki K, Ueno A, Tsujikawa H, et al.
Hepatol Res
. 2022 Dec;
53(4):344-356.
PMID: 36517953
Aim: WNT/β-catenin-activated hepatocellular carcinoma (W/B subclass HCC) is considered a molecularly homogeneous entity and has been linked to resistance to immunotherapy. However, recent studies have indicated possible heterogeneity in the...
10.
Iriki H, Takahashi H, Wada N, Nomura H, Mukai M, Kamata A, et al.
Proc Natl Acad Sci U S A
. 2021 Dec;
118(49).
PMID: 34848535
Antigen-specific peripheral tolerance is crucial to prevent the development of organ-specific autoimmunity. However, its function decoupled from thymic tolerance remains unclear. We used desmoglein 3 (Dsg3), a pemphigus antigen expressed...